Jatinder Lamba

Jatinder Lamba Ph.D., M.Sc.

Professor And Graduate Coordinator

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6425
Business Email: jlamba@cop.ufl.edu

About Jatinder Lamba

Dr. Jatinder Lamba is currently Professor in the Department of Pharmacotherapy and Translational Research. She did her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining University of Florida, she was an Associate Professor at University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy and the Director of the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine.

Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy. Dr. Lamba’s research on pharmacogenomics of anti-leukemic agents has been funded by NIH/NCI since 2008. Specifically, her current NCI funded R01 focuses on pharmacogenomics/ epigenomics of cytarabine (ara-C), a nucleoside analog that is the backbone of anti-leukemia chemotherapy in pediatric AML patients. Her group is working on developing algorithms to incorporate pharmacogenomics/epigenomic markers with other prognostic factors to advance precision medicine in oncology. Identification of such patients upfront will provide opportunity to tailor the initial chemotherapy to achieve maximum benefit.

Dr. Lamba’s lab is the first one to identify genetic polymorphisms in CD33 gene that are predictive of response to CD33 targeted agents in AML. These results hold promise in utilizing preemptive genotype to select patients most likely to benefit from CD33-directed therapy such as gemtuzumab ozogamicin in treating AML. Previous work on CD33 genomics was funded by NCI and more in-depth characterization of CD33 as AML therapeutic target is funded by a recent award from leukemia Lymphoma Society.

Given a critical gap of our understanding in metabolic dysregulation in AML, Dr. Lamba’s group is focused understanding the metabolomics differences and biomarkers of prognostic significance in pediatric AML. Dr. Lamba’s recent work is focused towards utilizing transcriptomics to build and refine leukemic stem cell signatures and AML drug response signatures of prognostic and predictive value in AML.

Dr. Lamba has served as chair of Pharmacogenomics SIG at AACP (2013) and is currently vice-chair of Pharmacogenomics focus group with AAPS. She has served as a grant reviewer for numerous NIH study sections and has reviewed grants for international agencies as Italian Ministry of Health. She has published more than 90 research articles in peer-reviewed journals and is on the editorial boards of Leukemia and Lymphoma, Pharmacogenomics and Frontiers in Pharmacogenomics and genomics, JCMM. Dr. Lamba is currently Professor in College of Pharmacy and is also Graduate Program coordinator for PTR department. Dr. Lamba is very committed towards training of future generation of scientist. She has trained 6 Ph. D students, 5 Post-doctoral fellows several Pharm D students and 3 hematology-oncology fellows and several under-graduate students including minority and underrepresented students.


July 2019ACTIVE
Personalizing CD33-directed immunotherapy for pediatric AML
CHILDRENS ONCOLOGY GROUP · Principal Investigator
July 2019ACTIVE
Personalizing CD33-directed Immunotherapy for Pediatric AML
LEUKEMIA & LYMPHOMA SOC · Principal Investigator
April 2019ACTIVE
Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
June 2018ACTIVE
OR-DRPD-ROD2018: Development of Leukemia-Oncotype Prototype CARS (Cytarabine AML Response Score) for Prediction of Relapse Risk in AML
UF OFFICE OF RESEARCH · Principal Investigator
February 2018 – January 2019
Impact of CD33 Genetics on Clinical Outcome in Pediatric AML Patients Treated on AAML0531 Clinical Trial
CHILDRENS ONCOLOGY GROUP · Principal Investigator
December 2016ACTIVE
Multiple Sponsors
MULTIPLE SPONSORS · Principal Investigator
September 2014ACTIVE
Pharmacogenomics of Ara-C in AML
NATL INST OF HLTH NCI · Principal Investigator


Postgraduate Institute of Medical Education and Research
Postgraduate Institute of Medical Education and Research
Panjab University

News Stories

Lamba’s Lab (Coming Soon)